MedTrace Logo

Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II (ORBIT-AF II)

NCT01701817 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 13769

Last updated 2025-02-03

No results posted yet for this study

Summary

The Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF II) is a multicenter, prospective outpatient disease registry to evaluate the utilization of target-specific antithrombotic agents, such as FXa (factor Xa) inhibitors and direct thrombin inhibitors, and associated outcomes. Importantly, the ORBIT AF II registry will permit the collection and analysis of post-approval observational data needed for evaluating the outcomes associated with these new agents when used in broader patient populations outside of clinical studies. The ORBIT-AF II registry will focus on patients with newly diagnosed atrial fibrillation (AF) as well as those who have been recently started on a target-specific oral anticoagulant agent. Taken together, the ORBIT-AF I and ORBIT-AF II registries will offer a broad and contemporary view of AF therapy.

Conditions

Interventions

OTHER

Patients with Atrial Fibrillation

Treatment patterns of AF according to patient demographics, clinical factors, risk stratification, and geographic regions.

Sponsors & Collaborators

  • Duke Clinical Research Institute

    collaborator OTHER

  • Bayer

    collaborator INDUSTRY

  • Janssen Scientific Affairs, LLC

    lead INDUSTRY

Principal Investigators

  • Janssen Scientific Affairs, LLC Clinical Trial · Janssen Scientific Affairs, LLC

Eligibility

Min Age
21 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-02-20
Primary Completion
2017-07-12
Completion
2017-07-12

Countries

  • United States
  • Puerto Rico
  • Virgin Islands

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01701817 on ClinicalTrials.gov